FDA Approved Peptide Drugs: 2 PDCs and Why Lists Differ

No agency publishes an FDA approved peptide drugs complete list, because approval attaches to a product application rather than to a molecular class. What the primary literature does document is narrow and checkable: two peptide-drug conjugates carry FDA approval for cancer treatment (Wang et al., Eur J Med Chem, 2024, PMID 38194773), and glucagon-like peptide-1 receptor agonists entered practice as one of three new type 2 diabetes classes approved on glycemic-control effects over the 15 years before 2018 (Mol et al., Diabetes Obes Metab, 2018, PMID 30294953). Any total larger than that is someone’s counting rule, and the rule is usually unstated.

Why isn’t there an official list of FDA approved peptide drugs?

Regulators count applications, not molecules. The cleanest published demonstration of what that does to a total comes from a single year of European decisions: the EMA recommended 114 new medicines for human use in 2024, of which 48 carried entirely novel active substances (Hu et al., Eur J Med Chem, 2025, PMID 40409054). Same agency, same twelve months, two defensible totals that differ by a factor of 114 / 48 = 2.4.

Put the other way, novel substances were 48 / 114 = 42.1% of that year’s recommendations. The remaining 58% were new products built on substances already authorized, which is exactly where reformulated insulins, new GLP-1 presentations and fixed-dose combinations land. A list that counts products will always run wide; a list that counts distinct peptide entities will always run narrow. Neither is wrong, and almost no published list says which one it used.

Orphan designation splits the same set again: 16 of the 114 (14%) 2024 recommendations were for rare disease treatments (PMID 40409054).

Which peptide drugs are documented as FDA approved?

Approval question	Counting rule	Figure	Source
Peptide-drug conjugates approved by FDA for cancer	finished PDC products	2	PMID 38194773
New type 2 diabetes drug classes approved on glycemic control, 15 years to 2018	classes, including GLP-1 receptor agonists	3	PMID 30294953
Oncology biosimilars approved 2007–2020, FDA	approved applications, one agency	16	PMID 33271114
Oncology biosimilars approved 2007–2020, EMA	approved applications, one agency	33	PMID 33271114
Oncology biosimilars approved 2007–2020, PMDA	approved applications, one agency	10	PMID 33271114
New medicines recommended by EMA, 2024	products recommended	114	PMID 40409054
Of those, entirely novel active substances	distinct new substances	48	PMID 40409054

Table 1: approval totals reported in four primary sources, with the counting rule each one used. Sources: Wang et al., Eur J Med Chem, 2024, PMID 38194773; Mol et al., Diabetes Obes Metab, 2018, PMID 30294953; Bennett et al., Lancet Oncol, 2020, PMID 33271114; Hu et al., Eur J Med Chem, 2025, PMID 40409054.

The peptide-drug conjugate figure is the most specific number in the set. Two PDCs have FDA approval for cancer, positioned in the literature as the successor format to antibody-drug conjugates, with enhanced tissue penetration, easier chemical synthesis and lower production costs as the stated advantages over ADCs (PMID 38194773).

The diabetes entry counts differently again. GLP-1 receptor agonists arrived alongside DPP-4 inhibitors and SGLT-2 inhibitors as three classes approved on glycemic control, with large randomized trials characterizing efficacy and safety at the population level while individualization questions stayed open (PMID 30294953). Only the GLP-1 class is peptide-based. DPP-4 and SGLT-2 inhibitors are orally dosed small molecules as a matter of general pharmacology rather than anything PMID 30294953 reports, and the split matters if you are reading how peptides compare with small molecules on route and dose burden. The class-level figure of 3 is not three drugs, and a list that treats it as three peptide drugs is already wrong by construction.

Does FDA approved mean the same thing in the EU or Japan?

It does not, and the biologic record shows the gap in hard numbers. Between 2007 and 2020, the same oncology biosimilar field produced 33 approvals at the EMA, 16 at the FDA and 10 at the PMDA (Bennett et al., Lancet Oncol, 2020, PMID 33271114). Over one shared window, EMA cleared 33 / 16 = 2.1 times as many applications as FDA, a difference of 17 products.

Initial rejection rates diverge further. Manufacturing concerns produced initial rejections in four of 36 applications (11%) at the EMA, seven of 16 (44%) at the FDA, and none of ten at the PMDA (PMID 33271114). Read as a ratio of rates rather than of counts, the FDA rejection rate is 44% / 11% = 4.0 times the EMA rejection rate — the two percentages sit on different denominators (16 applications at FDA, 36 at EMA), so the raw counts of seven and four are not in that proportion. The source reports a 36-application denominator for EMA rejections against a 33-approval headline in the same abstract; the three-application difference is not reconciled there, so treat the 11% as approximate rather than recomputing it.

Review speed runs the other direction from volume. Median times from initial submission to approval were 1.5 years at EMA, 1.3 years at FDA and 0.9 years at PMDA (PMID 33271114) — the PMDA median is 1.5 − 0.9 = 0.6 years faster than EMA, or about 7 months.

Approval also does not settle what a pharmacist may hand over. Substitution of a biosimilar for a reference biologic is permitted in some EU countries, prohibited in the USA unless the product is approved as interchangeable, and not permitted in Japan, where prescribers must name the product (PMID 33271114). At that review’s publication, no biosimilar in the USA had achieved interchangeable designation.

Why does the approved peptide list grow slowly?

The obstacles named in the PDC literature are pharmacokinetic and procedural rather than chemical: poor stability, short blood circulation time, a long research and development time frame and a slow clinical development process (PMID 38194773). Two approvals against that list of constraints is a proportionate result, not an anomaly.

Regulatory science has been moving to compensate. Accelerated pathways carried several 2024 EMA approvals through, including novel antibiotics against multidrug-resistant bacterial infections, the first drug shown to slow Alzheimer’s disease progression and the first vaccine protecting adults against chikungunya virus (PMID 40409054). On the diabetes side, few medicines have been approved for diabetic kidney disease at all, and initiatives on both sides of the Atlantic were launched specifically to make personalized development in that indication feasible (PMID 30294953).

How should you read a published list of approved peptides?

Start with what the sources will actually support by name. Asked which peptides are FDA approved now, the defensible answer from these four papers is two classes: glucagon-like peptide-1 receptor agonists, approved as one of the three new type 2 diabetes classes cleared on glycemic-control effects in the 15 years to 2018 (PMID 30294953), and peptide-drug conjugates, of which two products carry FDA approval for cancer (PMID 38194773). That is a class-level answer and a two-product answer, not a roster — which is the point. Anyone handing you a numbered roster has added a counting rule on top.

Check the counting rule first. A list that mixes a class count, a product count and a distinct-substance count produces a number that cannot be reconciled with any register, which is why totals in circulation disagree so widely.

Check the jurisdiction second. The 33 / 16 / 10 spread across EMA, FDA and PMDA over one window is the size of the error you inherit by treating “approved” as a single global state (PMID 33271114).

Check the date third, and check availability separately from approval. Approved status does not guarantee supply: the EMA implemented the European Shortages Monitoring Platform and stepped up stakeholder communication in 2024 specifically for critical medicines including GLP-1 receptor agonists (PMID 40409054), the same class whose 68-week trial figures by drug drove the demand that created the shortage.